Dr. Michael D. Weiss
Neurology (Neurology Physician)
University Of Washington Medical Ctr, 1959 Ne Pacific St
Seattle, WA 98195
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 232
Licensed in Washington since 2001, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
WA license MD00039454 (first issued 2001; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Washington Medical Ctr Seattle, WA
- Harborview Medical Center Seattle, WA
- Jefferson Healthcare Port Townsend, WA
Medical groups
- The Association of University Physicians (3,535 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 232
- Services billed
- 684
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 139 | 105 |
| Established patient office or other outpatient visit, 30-39 minutes | 63 | 56 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 41 | 29 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 19 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 14 | 14 |
| Nerve conduction, 7-8 studies | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Seattle, WA | 128 |
| Pregabalin Other prescribers in Seattle, WA | 101 |
| Prednisone Other prescribers in Seattle, WA | 79 |
| Gammagard Liquid (immun glob g(igg)/gly/iga ov50) | 79 |
| Radicava Ors (edaravone) | 71 |
| Mycophenolate Mofetil Other prescribers in Seattle, WA | 62 |
| Duloxetine Hcl Other prescribers in Seattle, WA | 58 |
| Nuedexta (dextromethorphan hbr/quinidine) Other prescribers in Seattle, WA | 55 |
| Pyridostigmine Bromide Other prescribers in Seattle, WA | 49 |
| Riluzole | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 10 companies reported 54 payments worth $32,102 in total to this clinician.
| UCB, Inc. | $12,235 |
|---|---|
| Amgen Inc. | $7,818 |
| Argenx US, Inc. | $7,278 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,297 |
| Genzyme Corporation | $1,830 |
| Janssen Scientific Affairs, LLC | $197 |
| Grifols Shared Services North America, Inc. | $143 |
| Csl Behring | $141 |
| Compensation for services other than consulting (speaking, faculty) | $15,450 |
|---|---|
| Consulting Fee | $9,068 |
| Travel and Lodging | $5,514 |
| Food and Beverage | $2,069 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $4,500 |
| Amgen Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,300 |
| UCB, Inc. Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $3,000 |
| Argenx US, Inc. Oct 14, 2025 | Consulting Fee | $2,188 |
| Argenx US, Inc. Nov 20, 2025 | Consulting Fee VYVGART · Immunology | $2,081 |
| Amgen Inc. Dec 17, 2025 | Travel and Lodging travel to Moscow, ID · in-kind | $1,941 |
| Genzyme Corporation Aug 22, 2025 | Consulting Fee | $1,830 |
| Argenx US, Inc. Oct 14, 2025 | Consulting Fee VYVGART · Immunology | $1,719 |
| Argenx US, Inc. Dec 19, 2025 | Consulting Fee VYVGART; VYVGART HYTRULO · Immunology | $1,250 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Dec 19, 2025 | Consulting Fee VYVGART; VYVGART HYTRULO · Immunology | $1,250 |
| Amgen Inc. Dec 17, 2025 | Travel and Lodging travel to Moscow, ID · in-kind | $1,941 |
| Amgen Inc. Dec 16, 2025 | Travel and Lodging travel to Spokane, WA | $182 |
| Amgen Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,100 |
| Amgen Inc. Dec 9, 2025 | Travel and Lodging travel to Moscow, ID · in-kind | $160 |
| Argenx US, Inc. Nov 20, 2025 | Consulting Fee VYVGART · Immunology | $2,081 |
| Amgen Inc. Nov 18, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,300 |
| Amgen Inc. Nov 18, 2025 | Travel and Lodging travel to Moscow, ID · in-kind | $287 |
| Amgen Inc. Nov 17, 2025 | Travel and Lodging travel to Seattle, WA | $14.55 |
| Argenx US, Inc. Oct 14, 2025 | Consulting Fee | $2,188 |
| Argenx US, Inc. Oct 14, 2025 | Consulting Fee VYVGART · Immunology | $1,719 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 4, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 3, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $474 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 1, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $259 |
| Amgen Inc. Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) UPLIZNA · Inflammation/Rare Disease | $550 |
| Genzyme Corporation Aug 22, 2025 | Consulting Fee | $1,830 |
| UCB, Inc. Apr 2, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $3,000 |
| UCB, Inc. Mar 20, 2025 | Travel and Lodging Zilbrysq · Neurology · travel to Tacoma, WA · in-kind | $908 |
| UCB, Inc. Mar 19, 2025 | Travel and Lodging Zilbrysq · Neurology · travel to Tacoma, WA · in-kind | $40.00 |
| UCB, Inc. Mar 4, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $4,500 |
| UCB, Inc. Mar 4, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Portland, OR · in-kind | $259 |
| UCB, Inc. Feb 4, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $206,972 in research payments for these studies, mostly to the institutions running them.
- A phase 2, randomized, double-blind, placebo-controlled parallel group study of VHB937 in Amyotrophic Lateral Sclerosis (ALS) over 40 weeks followed by an Open-label Extension (ASTRALS)
Novartis Pharmaceuticals Corporation - A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab)…
Argenx US, Inc. - Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
UCB SA · Completed · NCT04225871 - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB SA · Completed · NCT05514873
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.